Clinical trials: Mental Depression
Treatment Resistant Depression, Depressive Disorder
A Clinical Evaluation of Subcallosal Cingulate Gyrus Deep Brain Stimulation for Treatment-Resistant Depression
This is a randomized, placebo-controlled double-blind cross-over trial evaluating the safety, efficacy, daily functioning, and health-related quality of life of Subcallosal Cingulate Gyrus Deep Brain Stimulation (SCG DBS) for…
- Trial name
- NCT01801319
- Testing
- Libra Deep Brain Stimulation System
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Abbott Medical Devices
Major Depressive Disorder
Safety and Efficacy Study Comparing ETS6103 With Amitriptyline in the Treatment of Major Depressive Disorder (MDD)
To demonstrate that the antidepressant activity of ETS6103 is not inferior to amitriptyline in subjects who have an unsatisfactory response to / are resistant to treatment with SSRIs.
- Trial name
- ETS6103-003 (NCT02014363)
- Testing
- ETS6103 (low dose), ETS6103 (high dose), Amitriptyline
- Where
- United Kingdom
- Volunteers
- 164 people
- Sponsor
- e-Therapeutics PLC
Atopic Dermatitis
A Study to Evaluate the Quality of Life of Male and Female Adult Patients With Severe Refractory Atopic Dermatitis Treated With Dupilumab in Czech Republic
Assessment of the relationship between treatment response (EASI75) and change in quality of life (EQ-5D) by week 24. Description of the: Change in disease activity after 16 and 24 weeks Change in subject and family quality of…
- Trial name
- NCT05527964
- Where
- Czechia
- Volunteers
- 146 people
- Sponsor
- Sanofi
Depressive Episodes, Bipolar I Depression
A Clinical Trial to Determine the Long-term Safety and Tolerability of an Investigational Drug in People With Major Depressive Episode Associated With Bipolar I Disorder (Bipolar I Depression).
This is a clinical trial to determine the long-term safety and tolerability of an investigational drug in people with Major Depressive Episode Associated with Bipolar I Disorder (Bipolar I Depression).
- Trial name
- NCT05227209
- Testing
- SEP-4199 CR
- Where
- 69 sites in United States, Bulgaria and 1 more
- Volunteers
- 64 people
- Sponsor
- Sumitomo Pharma America, Inc.
Depressive Disorder
An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Elderly Patients With Depression
The purpose of the study is to evaluate the efficacy and safety of SR58611A in elderly patients with depression.The primary objective is to evaluate the efficacy of a 700 mg dose of SR58611A compared to placebo in elderly…
- Trial name
- ZEPHIR (NCT00319709)
- Testing
- SR58611A
- Where
- 5 sites in Bulgaria, Finland and 3 more
- Volunteers
- 288 people
- Sponsor
- Sanofi
Depressive Disorder
An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Depression
The purpose of the study is to evaluate the efficacy and safety of saredutant (or SR48968C) in patients with depression. The primary objective is to evaluate the efficacy of a 100 mg dose of saredutant compared to placebo in…
- Trial name
- NCT00250614
- Testing
- Saredutant succinate (SR48968C)
- Where
- United States
- Volunteers
- 452 people
- Sponsor
- Sanofi
Major Depressive Disorder
Open Label Optimization Study
The goal of this observational study is to demonstrate effectiveness in the treatment of Major Depressive Disorder The primary objective is to assess the effectiveness in the treatment of Major Depressive Disorder using the CGI-I…
- Trial name
- OLO (NCT05819021)
- Testing
- SAINT® Neuromodulation System (NMS)
- Where
- 7 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Magnus Medical
Depression
PK Study of Multi-dose Trazodone Hydrochloride Prolonged-released Tablets in Healthy Chinese
The main objective is to evaluate the pharmacokinetics comparative studies in a single dose, multiple dose
- Trial name
- NCT02785614
- Testing
- trazodone hydrochloride prolonged-release tablet, trazodone hydrochloride tablet
- Where
- Hong Kong
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Lee's Pharmaceutical Limited
Insomnia, Depression
Study Of Indiplon/Placebo With Sertraline In Insomnia Co-Existing With Depression
The goal of this study is to determine whether indiplon, when administered with sertraline, improves insomnia symptoms and depressive symptoms in subjects with both insomnia and depression.
- Trial name
- NCT00232167
- Testing
- Indiplon, Sertraline
- Volunteers
- 380 people
- Sponsor
- Neurocrine Biosciences
Bipolar Disorder I or II With a Major Depressive Episode
ALTO-100 in Bipolar Disorder With Depression (BD-D)
The purpose of this study is to assess antidepressant efficacy differences between ALTO-100 and placebo during the Double-Blind period in patients with bipolar disorder I or II with current major depressive episode, when used…
- Trial name
- NCT06656416
- Testing
- ALTO-100
- Where
- 68 sites in United States, United Kingdom
- Volunteers
- 200 people
- Sponsor
- Alto Neuroscience
Suicide, Mental Health Disorder
A Digitally Assisted Risk Reduction Platform for Youth at High Risk for Suicide
Despite efforts to prevent suicide, US rates are climbing, and suicide is the second leading cause of death among youth. Digital tools, especially personal smartphones, are promising avenues to address these issues and can be…
- Conditions
- Suicide, Mental Health Disorder, Anhedonia
- Trial name
- NCT05920252
- Testing
- Vira, Treatment as Usual (TAU)
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- Ksana Health
Depression
Multiple-Ascending Dose Study
The purpose of this study is to determine the safety and tolerability of BMS-820836 after multiple doses
- Trial name
- NCT00892840
- Testing
- BMS-820836
- Where
- Sweden
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Major Depressive Disorder
A Study Comparing Duloxetine and Placebo in Assessing Energy and Vitality in Major Depressive Disorder (MDD) Patients
Study F1J-US-HMFS comprises two identical multicenter, 9-month, randomized, placebo-controlled, double-blind, trials (HMFSa and HMFSb).
- Trial name
- NCT00536471
- Testing
- Duloxetine hydrochloride
- Where
- 47 sites in United States, Puerto Rico
- Volunteers
- 776 people
- Sponsor
- Eli Lilly and Company
Treatment Resistant Depression
The RECOVER sUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes
The objective of this study is to collect both active and passive data using a wearable, multi-sensor device (Verily Study Watch) and phone application (Mood App) which aims to capture mental health status, in subjects…
- Trial name
- UNCOVER (NCT04753385)
- Where
- 33 sites in United States
- Volunteers
- 138 people
- Sponsor
- LivaNova
Depression Disorders, Anxiety Disorders
Validate the Temporal Stability and Responsiveness of AI-COA® for Depression and Anxiety
This study evaluates the reliability and responsiveness of the AI-COA®, a digital tool designed to assess the severity of depression and anxiety.
- Trial name
- SEQUOIA-2 (NCT07279025)
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Deliberate Solutions Inc.
Seasonal Affective Disorder
Prevention of Seasonal Affective Disorder
This is a placebo controlled study evaluating the effectiveness of medication in preventing depressive episodes in subjects with a history of Seasonal Affective Disorder (SAD).
- Trial name
- NCT00046241
- Testing
- Extended-release bupropion hydrochloride
- Where
- 51 sites in United States, Canada
- Volunteers
- 300 people
- Sponsor
- GlaxoSmithKline
Insomnia
Ambien CR For Treatment Of Insomnia Associated With Depression When Used Concomitantly With Lexapro
To demonstrate overall improvement of insomnia in subjects treated with zolpidem tartrate extended-release (Ambien CR) and escitalopram (Lexapro) vs. subjects treated with placebo and escitalopram at 2 months.
- Trial name
- NCT00296179
- Testing
- zolpidem tartrate
- Volunteers
- 372 people
- Sponsor
- Sanofi
Depressive Disorder
Study to Evaluate the Safety and Efficacy of PEER Interactive Versus Treatment as Usual in Subjects With a Primary Diagnosis of Depression
This is a prospective, multicenter, randomized, double-blind, controlled study to evaluate the effectiveness of PEER Interactive to inform treatment in subjects with a primary diagnosis of depression with comorbidity of…
- Trial name
- NCT01794559
- Testing
- PEER Interactive Report
- Where
- 2 sites in United States
- Volunteers
- 1,922 people
- Sponsor
- MYnd Analytics
Major Depressive Disorder
A Study to Evaluate the Safety and Efficacy of TS-121 as an Adjunctive Treatment for Major Depressive Disorder
The purpose of this study is to evaluate the safety, tolerability, and efficacy of TS-121 as an adjunctive treatment for patients with major depressive disorder with an inadequate response to current antidepressant Treatment…
- Trial name
- NCT03093025
- Testing
- TS-121 10 mg, TS-121 50 mg
- Where
- 22 sites in United States
- Volunteers
- 51 people
- Sponsor
- Taisho Pharmaceutical R&D Inc.
Postpartum Depression
A Study to Evaluate Safety and Efficacy of SAGE-547 in Participants With Moderate Postpartum Depression (547-PPD-202C)
The purpose of this study was to determine if SAGE-547 Injection infused intravenously at up to 90 μg/kg/h for 60 hours reduces depressive symptoms in participants with moderate postpartum depression (PPD) compared to placebo…
- Trial name
- NCT02942017
- Testing
- SAGE-547 90 μg/kg/h
- Where
- 32 sites in United States
- Volunteers
- 108 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.